AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03106142 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Academic detailing visit arm
Description: General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
Study NCT01475123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: 15mg per day
Study NCT04432688 — intervention group
Intervention type: DRUG
Intervention: Lurasidone HCl
Description: This is a non-interventional, observational study
Study NCT04468698 — intervention group
Intervention type: OTHER
Intervention: Peritoneum insufflation
Description: Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
Study NCT03601780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local wound infiltration plus usual care
Description: local wound infiltration plus usual care
Study NCT03601780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: usual care only
Description: usual care only
Study NCT01815008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily
Study NCT01815008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81 mg daily
Study NCT01474707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group one
Description: Group 1 will view the knowledge-based video only
Study NCT01474707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group two
Description: Group two will view the motivational video only
Study NCT01474707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group three
Description: Group three will view both knowledge-based and motivational videos
Study NCT01474707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group four
Description: Group four will view the printed educational pamphlet and will not view either video
Study NCT01365208 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: platinum-based chemotherapy
Study NCT02983617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Administered orally once daily
Study NCT02983617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Administered orally once daily
Study NCT02983617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study NCT03221023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
Study NCT03221023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Individuals in the control arm will receive intrawound saline solution
Study NCT03221023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Individuals in the control arm will receive intrawound saline solution
Study NCT00831272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 50mg/day
Study NCT00831272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04187664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Monitoring
Description: Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
Study NCT04187664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin testing
Description: High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
Study NCT00596310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT
Description: Screening CT
Study NCT00152191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
Study NCT00152191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide, methotrexate, and fluorouracil
Description: cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detailed baseline interview, enhanced HIV intervention
Description: Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General baseline interview, enhanced HIV intervention
Description: Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No baseline interview, enhanced HIV intervention
Description: This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Detailed baseline interview, standard of care intervention
Description: Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General baseline interview, standard of care intervention
Description: Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
Study NCT01580657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No baseline interview, standard of care intervention
Description: Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
Study NCT05790148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3Shape
Description: original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Impulse oscillometry
Description: Impulse oscillometry test will be applied to all groups.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometric pulmonary function test
Description: Spirometric pulmonary function test will be applied to all groups.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional exhaled nitric oxide (FENO) test
Description: FeNO test will be applied to asthma group.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thorax Computed Tomography
Description: Thorax Computed Tomography will be taken to the asthma group.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood eosinophil level
Description: The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
Study NCT04375995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Asthma control test
Description: Asthma control test questions will be applied to the asthma group.
Study NCT04375995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Asthma quality of life scale
Description: Asthma quality of life scale (AQLQ) will be applied to the asthma group.
Study NCT04375995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest X Ray
Description: Chest X Ray will be applied to the healthy control group.
Study NCT01671982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Dose Adjustment
Description: In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
Study NCT00462891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IT System
Study NCT03937661 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Autologous PFP intra ovarian infusion
Study NCT01006395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: yearly infusion
Study NCT01006395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: yearly infusion
Study NCT03360994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WATChmAN Active Surveillance
Description: WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
Study NCT03360994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Active Surveillance
Description: In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
Study NCT02057445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV CTL's
Description: Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
Study NCT02057445 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral Blood Donor
Description: Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
Study NCT03974165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-legume product 1
Description: The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
Study NCT03974165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-legume product 2
Description: The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
Study NCT03974165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product
Description: The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
Study NCT03974165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference food
Description: The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
Study NCT00021060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: Corticosteroids standard dose.
Study NCT01421914 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bupivacaine 0,5%
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
Study NCT01213329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
Study NCT02284191 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT Coronary Angiogram
Description: Completion of a CT Coronary Angiogram
Study NCT03670368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
Study NCT03051191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
Study NCT03670368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison group - written materials
Description: Written materials from the mentoring sessions will be provided to those in the comparison group
Study NCT00021060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01130467 — intervention group
Intervention type: DRUG
Intervention: methylphenidate
Description: IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Gel
Description: Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints.
Study NCT00021060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00021060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Gel
Description: Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints.
Study NCT00608595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal TFV Gel
Description: Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Study NCT01448616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Study NCT04204824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound and exercise
Description: The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home
Study NCT04204824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise
Description: The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home
Study NCT04641832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study NCT04641832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study NCT03139448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen via nasal cannula
Description: Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
Study NCT03139448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen via SuperNO2VA nasal mask
Description: The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
Study NCT00392015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA
Description: Malaria Vaccine